Drug Class
antineoplastic agents

Available Guidelines

  1. CPIC Guideline for capecitabine and DPYD
  2. CPIC Guideline for fluorouracil and DPYD
  3. CPIC Guideline for mercaptopurine and TPMT
  4. CPIC Guideline for thioguanine and TPMT
  5. PRO Guideline for irinotecan and UGT1A1
  6. PRO Guideline for daunorubicin,doxorubicin and RARG,SLC28A3,UGT1A5
  7. DPWG Guideline for capecitabine and DPYD
  8. DPWG Guideline for fluorouracil and DPYD
  9. DPWG Guideline for irinotecan and UGT1A1
  10. DPWG Guideline for mercaptopurine and TPMT
  11. DPWG Guideline for thioguanine and TPMT

last updated 09/15/2016

1. CPIC Guideline for capecitabine and DPYD

Summary

The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (rs3918290), *13 (rs55886062), and rs67376798 A (on the positive chromosomal strand) - as these patients are typically DPD deficient. Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).

There's more of this guideline. Read more.


last updated 09/15/2016

2. CPIC Guideline for fluorouracil and DPYD

Summary

The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (rs3918290), *13 (rs55886062), and rs67376798 A (on the positive chromosomal strand) - as these patients are typically DPD deficient. Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).

There's more of this guideline. Read more.


last updated 09/15/2016

3. CPIC Guideline for mercaptopurine and TPMT

Summary

Start with reduced doses of mercaptopurine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.

There's more of this guideline. Read more.


last updated 09/15/2016

4. CPIC Guideline for thioguanine and TPMT

Summary

Start with reduced doses of thioguanine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.

There's more of this guideline. Read more.


last updated 06/03/2015

5. PRO Guideline for irinotecan and UGT1A1

Summary

A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype.

There's more of this guideline. Read more.


6. PRO Guideline for daunorubicin,doxorubicin and RARG,SLC28A3,UGT1A5

Summary

The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).

There's more of this guideline. Read more.


last updated 02/07/2014

7. DPWG Guideline for capecitabine and DPYD

Summary

Select an alternate drug to capecitabine for DPYD poor metabolizer patients, and reduce capecitabine dose (by 50%) or select an alternate drug for DPYD intermediate metabolizers.

There's more of this guideline. Read more.


last updated 02/07/2014

8. DPWG Guideline for fluorouracil and DPYD

Summary

An alternative drug rather than fluorouracil is recommended for DPYD poor metabolizer patients, and a reduced dose (by 50%) of fluorouracil or use of an alternative drug is recommended for intermediate metabolizer patients.

There's more of this guideline. Read more.






Annotated Labels

  1. FDA Label for afatinib and EGFR
  2. FDA Label for afutuzumab and MS4A1
  3. FDA Label for alemtuzumab
  4. FDA Label for arsenic trioxide and PML,RARA
  5. FDA Label for asparaginase
  6. FDA Label for bevacizumab
  7. FDA Label for bleomycin
  8. FDA Label for bortezomib
  9. FDA Label for bosutinib and ABL1,BCR
  10. FDA Label for brentuximab vedotin and TNFRSF8
  11. FDA Label for busulfan and ABL1,BCR
  12. FDA Label for capecitabine and DPYD
  13. FDA Label for carboplatin
  14. FDA Label for carmustine
  15. FDA Label for celecoxib and CYP2C9
  16. FDA Label for ceritinib and ALK
  17. FDA Label for cetuximab and EGFR,KRAS
  18. FDA Label for chlorambucil
  19. FDA Label for cisplatin and TPMT
  20. FDA Label for crizotinib and ALK
  21. FDA Label for cyclophosphamide
  22. FDA Label for cytarabine
  23. FDA Label for dabrafenib and BRAF
  24. FDA Label for dabrafenib and G6PD
  25. FDA Label for dacarbazine
  26. FDA Label for dasatinib and ABL1,BCR
  27. FDA Label for daunorubicin
  28. FDA Label for denileukin diftitox and IL2RA
  29. FDA Label for docetaxel
  30. FDA Label for doxorubicin
  31. FDA Label for epirubicin
  32. FDA Label for erlotinib and EGFR
  33. FDA Label for estramustine
  34. FDA Label for etoposide
  35. FDA Label for fludarabine
  36. FDA Label for fluorouracil and DPYD
  37. FDA Label for gefitinib and EGFR
  38. FDA Label for gemcitabine
  39. FDA Label for homoharringtonine and ABL1,BCR
  40. FDA Label for hydroxyurea
  41. FDA Label for ibrutinib
  42. FDA Label for idarubicin
  43. FDA Label for ifosfamide
  44. FDA Label for imatinib and ABL1,BCR,KIT
  45. FDA Label for irinotecan and UGT1A1
  46. FDA Label for Ixabepilone
  47. FDA Label for melphalan
  48. FDA Label for mercaptopurine and TPMT
  49. FDA Label for methotrexate
  50. FDA Label for mitoxantrone
  51. FDA Label for ofatumumab and MS4A1
  52. FDA Label for oxaliplatin
  53. FDA Label for paclitaxel
  54. FDA Label for panitumumab and EGFR,KRAS
  55. FDA Label for pazopanib and UGT1A1
  56. FDA Label for pemetrexed
  57. FDA Label for pertuzumab and ERBB2
  58. FDA Label for ponatinib and ABL1,BCR
  59. FDA Label for procarbazine
  60. FDA Label for regorafenib and EGFR,KRAS,VEGFA
  61. FDA Label for rituximab and MS4A1
  62. FDA Label for sorafenib
  63. FDA Label for sunitinib
  64. FDA Label for temozolomide
  65. FDA Label for temsirolimus
  66. FDA Label for teniposide
  67. FDA Label for thioguanine and TPMT
  68. FDA Label for thiotepa
  69. FDA Label for topotecan
  70. FDA Label for trametinib and BRAF
  71. FDA Label for trastuzumab and ERBB2
  72. FDA Label for trastuzumab emtansine and ERBB2
  73. FDA Label for tretinoin and PML,RARA
  74. FDA Label for vemurafenib and BRAF
  75. FDA Label for vincristine
  76. FDA Label for vinorelbine
  77. EMA Label for afatinib and EGFR
  78. EMA Label for arsenic trioxide and PML,RARA
  79. EMA Label for axitinib and CYP2C19,UGT1A1
  80. EMA Label for bosutinib and ABL1,BCR
  81. EMA Label for brentuximab vedotin and TNFRSF8
  82. EMA Label for capecitabine and DPYD
  83. EMA Label for ceritinib and ALK
  84. EMA Label for cetuximab and EGFR,KRAS
  85. EMA Label for crizotinib and ALK
  86. EMA Label for dabrafenib and BRAF
  87. EMA Label for dasatinib and ABL1,BCR
  88. EMA Label for erlotinib and EGFR,UGT1A1
  89. EMA Label for gefitinib and CYP2D6,CYP3A4,EGFR
  90. EMA Label for ibrutinib
  91. EMA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRB
  92. EMA Label for mercaptopurine and TPMT
  93. EMA Label for ofatumumab and MS4A1
  94. EMA Label for panitumumab and KRAS
  95. EMA Label for pazopanib and UGT1A1
  96. EMA Label for pertuzumab and ERBB2
  97. EMA Label for ponatinib and ABL1,BCR
  98. EMA Label for regorafenib and KRAS,UGT1A1
  99. EMA Label for rituximab and MS4A1
  100. EMA Label for sunitinib and CYP3A4
  101. EMA Label for trametinib and BRAF
  102. EMA Label for trastuzumab and ERBB2
  103. EMA Label for trastuzumab emtansine and ERBB2
  104. EMA Label for vandetanib and RET
  105. EMA Label for vemurafenib and BRAF
  106. PMDA Label for arsenic trioxide and PML,RARA
  107. PMDA Label for capecitabine and DPYD
  108. PMDA Label for celecoxib and CYP2C9
  109. PMDA Label for cetuximab and EGFR,KRAS
  110. PMDA Label for crizotinib and ALK
  111. PMDA Label for dasatinib and ABL1,BCR
  112. PMDA Label for fluorouracil and DPYD
  113. PMDA Label for gefitinib and EGFR
  114. PMDA Label for imatinib and ABL1,BCR,FIP1L1,KIT,PDGFRA
  115. PMDA Label for irinotecan and UGT1A1
  116. PMDA Label for panitumumab and KRAS
  117. PMDA Label for trastuzumab and ERBB2
  118. PMDA Label for tretinoin and PML,RARA
  119. HCSC Label for afatinib and EGFR
  120. HCSC Label for afutuzumab and MS4A1
  121. HCSC Label for arsenic trioxide and PML,RARA
  122. HCSC Label for bosutinib and ABL1,BCR
  123. HCSC Label for brentuximab vedotin and TNFRSF8
  124. HCSC Label for capecitabine and DPYD
  125. HCSC Label for celecoxib and CYP2C9
  126. HCSC Label for ceritinib and ALK
  127. HCSC Label for cetuximab and EGFR,KRAS
  128. HCSC Label for crizotinib and ALK
  129. HCSC Label for dabrafenib and BRAF
  130. HCSC Label for dasatinib and ABI1,BCR
  131. HCSC Label for erlotinib and EGFR
  132. HCSC Label for fluorouracil and DPYD
  133. HCSC Label for gefitinib and EGFR
  134. HCSC Label for ibrutinib
  135. HCSC Label for imatinib and ABI1,BCR,FIP1L1,KIT,PDGFRA,PDGFRB
  136. HCSC Label for irinotecan and UGT1A1
  137. HCSC Label for mercaptopurine and TPMT
  138. HCSC Label for panitumumab and EGFR,KRAS
  139. HCSC Label for pertuzumab and ERBB2
  140. HCSC Label for ponatinib and ABI1,BCR
  141. HCSC Label for thioguanine and TPMT
  142. HCSC Label for trametinib and BRAF
  143. HCSC Label for trastuzumab and ERBB2
  144. HCSC Label for trastuzumab emtansine and ERBB2
  145. HCSC Label for tretinoin and PML,RARA
  146. HCSC Label for vemurafenib and BRAF



















































































































































PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for antineoplastic agents

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1xN N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *7 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10x2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *20 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *21 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *35 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *36 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *41 N/A N/A N/A
No VIP available No VIP available VA UGT2B15 *1 N/A N/A N/A
No VIP available No VIP available VA UGT2B15 *2 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 extensive metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2D6 poor metabolizers N/A N/A N/A
No VIP available CA No Variant Annotations available
rs1042522 NC_000017.10:g.7579472G=, NC_000017.10:g.7579472G>C, NC_000017.10:g.7579472G>T, NC_000017.11:g.7676154G=, NC_000017.11:g.7676154G>C, NC_000017.11:g.7676154G>T, NG_017013.2:g.16397C=, NG_017013.2:g.16397C>A, NG_017013.2:g.16397C>G, NM_000546.5:c.215C=, NM_000546.5:c.215C>A, NM_000546.5:c.215C>G, NM_001126112.2:c.215C=, NM_001126112.2:c.215C>A, NM_001126112.2:c.215C>G, NM_001126113.2:c.215C=, NM_001126113.2:c.215C>A, NM_001126113.2:c.215C>G, NM_001126114.2:c.215C=, NM_001126114.2:c.215C>A, NM_001126114.2:c.215C>G, NM_001126115.1:c.-939C=, NM_001126115.1:c.-939C>A, NM_001126115.1:c.-939C>G, NM_001126116.1:c.-939C=, NM_001126116.1:c.-939C>A, NM_001126116.1:c.-939C>G, NM_001126117.1:c.-939C=, NM_001126117.1:c.-939C>A, NM_001126117.1:c.-939C>G, NM_001126118.1:c.98C=, NM_001126118.1:c.98C>A, NM_001126118.1:c.98C>G, NM_001276695.1:c.98C=, NM_001276695.1:c.98C>A, NM_001276695.1:c.98C>G, NM_001276696.1:c.98C=, NM_001276696.1:c.98C>A, NM_001276696.1:c.98C>G, NM_001276697.1:c.-1020C=, NM_001276697.1:c.-1020C>A, NM_001276697.1:c.-1020C>G, NM_001276698.1:c.-1020C=, NM_001276698.1:c.-1020C>A, NM_001276698.1:c.-1020C>G, NM_001276699.1:c.-1020C=, NM_001276699.1:c.-1020C>A, NM_001276699.1:c.-1020C>G, NM_001276760.1:c.98C=, NM_001276760.1:c.98C>A, NM_001276760.1:c.98C>G, NM_001276761.1:c.98C=, NM_001276761.1:c.98C>A, NM_001276761.1:c.98C>G, NP_000537.3:p.Pro72=, NP_000537.3:p.Pro72Arg, NP_000537.3:p.Pro72His, NP_001119584.1:p.Pro72=, NP_001119584.1:p.Pro72Arg, NP_001119584.1:p.Pro72His, NP_001119585.1:p.Pro72=, NP_001119585.1:p.Pro72Arg, NP_001119585.1:p.Pro72His, NP_001119586.1:p.Pro72=, NP_001119586.1:p.Pro72Arg, NP_001119586.1:p.Pro72His, NP_001119590.1:p.Pro33=, NP_001119590.1:p.Pro33Arg, NP_001119590.1:p.Pro33His, NP_001263624.1:p.Pro33=, NP_001263624.1:p.Pro33Arg, NP_001263624.1:p.Pro33His, NP_001263625.1:p.Pro33=, NP_001263625.1:p.Pro33Arg, NP_001263625.1:p.Pro33His, NP_001263689.1:p.Pro33=, NP_001263689.1:p.Pro33Arg, NP_001263689.1:p.Pro33His, NP_001263690.1:p.Pro33=, NP_001263690.1:p.Pro33Arg, NP_001263690.1:p.Pro33His, XM_005256778.1:c.176-21C=, XM_005256778.1:c.176-21C>A, XM_005256778.1:c.176-21C>G, XR_243565.1:n.354C=, XR_243565.1:n.354C>A, XR_243565.1:n.354C>G, XR_243566.1:n.354C=, XR_243566.1:n.354C>A, XR_243566.1:n.354C>G, rs17844988, rs17857747, rs17882155, rs2229076, rs3174747, rs4134781, rs60388830
G > C
SNP
P72R
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1059829 NC_000005.10:g.151662468G>A, NC_000005.9:g.151042029G>A, NG_042174.1:g.29587C>T, NM_001309443.1:c.*1103C>T, NM_001309444.1:c.*987C>T, NM_003118.3:c.*1103C>T, rs17718221, rs1804457, rs3210713, rs3822701, rs59831535
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available CA VA
rs17091162 NC_000014.8:g.95089232C>A, NC_000014.9:g.94622895C>A, NG_012879.1:g.15519C>A, NM_001085.4:c.1068+404C>A, XM_005267307.1:c.1143+404C>A, XM_005267308.1:c.1068+404C>A, XR_245663.1:n.899+404C>A, rs60560586
C > A
SNP
No VIP available CA VA
rs1760217 NC_000001.10:g.97602994A>G, NC_000001.11:g.97137438A>G, NG_008807.2:g.788622T>C, NM_000110.3:c.2623-38806T>C, NR_046590.1:n.64+41452A>G, XM_005270561.1:c.2512-38806T>C, XM_005270562.1:c.2407-38806T>C, XM_005270562.3:c.2407-38806T>C, rs17472184, rs58395723
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available No Clinical Annotations available VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2231164 NC_000004.11:g.89015857C>T, NC_000004.12:g.88094705C>T, NG_032067.2:g.141618G>A, NM_001257386.1:c.1728-46G>A, NM_004827.2:c.1738-46G>A, XM_005263354.1:c.1738-46G>A, XM_005263354.2:c.1738-46G>A, XM_005263355.1:c.1738-46G>A, XM_005263355.2:c.1738-46G>A, XM_005263356.1:c.1732-46G>A, XM_005263356.2:c.1732-46G>A, XM_011532420.1:c.1738-46G>A, rs3816742, rs386561805, rs59707155
C > A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2274407 NC_000013.10:g.95859035C>A, NC_000013.11:g.95206781C>A, NM_001105515.2:c.912G>T, NM_001301829.1:c.912G>T, NM_001301830.1:c.687G>T, NM_005845.4:c.912G>T, NP_001098985.1:p.Lys304Asn, NP_001288758.1:p.Lys304Asn, NP_001288759.1:p.Lys229Asn, NP_005836.2:p.Lys304Asn, XM_005254025.1:c.783G>T, XM_005254025.2:c.783G>T, XM_005254026.1:c.912G>T, XM_005254027.1:c.687G>T, XM_005254028.1:c.687G>T, XM_006719914.1:c.912G>T, XM_011521047.1:c.363G>T, XP_005254082.1:p.Lys261Asn, XP_005254083.1:p.Lys304Asn, XP_005254084.1:p.Lys229Asn, XP_005254085.1:p.Lys229Asn, XP_006719977.1:p.Lys304Asn, XP_011519349.1:p.Lys121Asn, rs117944872, rs52813831, rs58221897
C > A
SNP
K304N
No VIP available No Clinical Annotations available VA
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3795247
T > C
SNP
No VIP available No Clinical Annotations available VA
rs4502225 NC_000016.10:g.78390934T>C, NC_000016.9:g.78424831T>C, NG_011698.1:g.296281T>C, NM_001291997.1:c.266+3986T>C, NM_016373.3:c.605+3986T>C, XM_005255980.1:c.409+275780T>C, XM_005255981.1:c.266+3986T>C, XM_005255982.1:c.516+226645T>C, XM_006721195.2:c.605+3986T>C, XM_011523100.1:c.605+3986T>C, XM_011523101.1:c.605+3986T>C, XM_011523102.1:c.605+3986T>C, XM_011523103.1:c.605+3986T>C, XM_011523104.1:c.605+3986T>C, XR_243411.1:n.730+3986T>C, rs60064696
T > C
SNP
No VIP available No Clinical Annotations available VA
rs4910232
A > G
SNP
No VIP available CA VA
rs6500843 NC_000016.10:g.6820854A>G, NC_000016.9:g.6870855A>G, NG_011881.1:g.806724A>G, NM_001142333.1:c.-16+166204A>G, NM_001142334.1:c.-16+46841A>G, NM_001308117.1:c.114+166204A>G, NM_018723.3:c.-16+166204A>G, XM_005255378.1:c.462+166204A>G, XM_005255379.1:c.114+166204A>G, XM_005255379.2:c.114+166204A>G, XM_005255380.1:c.93+166204A>G, XM_005255380.2:c.93+166204A>G, XM_005255384.1:c.-16+166204A>G, XM_005255384.2:c.-16+166204A>G, XM_005255385.1:c.-16+166204A>G, XM_005255385.3:c.-16+166204A>G, XM_005255389.1:c.114+166204A>G, XM_005255389.2:c.114+166204A>G, XM_005255390.1:c.-16+166204A>G, XM_005255390.2:c.-16+166204A>G, XM_005255391.1:c.-16+166204A>G, XM_005255391.2:c.-16+166204A>G, XM_005255392.1:c.-16+166204A>G, XM_005255395.1:c.93+166204A>G, XM_011522544.1:c.462+166204A>G, rs60379811
A > G
SNP
No VIP available No Clinical Annotations available VA
rs6674079
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA452621

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to antineoplastic agents: 56

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Johnatty Sharon E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast cancer research and treatment. 2015. Ellingson Marissa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Pui Ching-Hon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget. 2015. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. PloS one. 2015. Shamai Sivan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients. Cancer chemotherapy and pharmacology. 2014. Tulsyan Sonam, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. 2014. Martins D M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer chemotherapy and pharmacology. 2014. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?. Clinical pharmacology and therapeutics. 2014. Bins S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Medical oncology (Northwood, London, England). 2014. Zhao Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic oncology. 2013. Johnatty Sharon E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast cancer research and treatment. 2013. Dezentjé V O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics. 2013. Margolin Sara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. Cancer chemotherapy and pharmacology. 2013. Trojan Andreas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmacogenomics and personalized medicine. 2013. Chamnanphon Montri, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer chemotherapy and pharmacology. 2012. Damodaran Solai Elango, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. The pharmacogenomics journal. 2012. Winder T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast cancer research and treatment. 2012. Park In Hae, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pacific journal of cancer prevention : APJCP. 2012. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. Journal of Korean medical science. 2011. Park Hyung Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011. van Schaik Ron H N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas. 2011. Zeng Hongmei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. Journal of the National Cancer Institute. 2011. Lash Timothy L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast cancer research and treatment. 2011. Thompson Alastair M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer epidemiology. 2010. Henríquez-Hernández Luis Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatric hematology and oncology. 2010. Horinouchi Masanori, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenetics and genomics. 2010. Kiyotani Kazuma, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast cancer research and treatment. 2010. Ramón y Cajal T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British journal of pharmacology. 2010. Zhou Fanfan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009. Ansari Marc, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer chemotherapy and pharmacology. 2009. Kim Jong Gwang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009. Okishiro Masatsugu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009. Chang H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. Journal of experimental therapeutics & oncology. 2009. Ishikawa Toshihisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. Journal of cancer research and clinical oncology. 2008. Huang Zhao-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Newman William G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008. Xu Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008. Ward Michael B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Moyer Ann M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British journal of haematology. 2007. Bolufer Pascual, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Yang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer research. 2005. Huang Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast cancer research and treatment. 2005. Nowell Susan A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast cancer research : BCR. 2005. Wegman Pia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004. Nückel H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics. 2004. Kaiser Rolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003. Tremblay Pierre-Benoit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Liu Wanqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays : news and reviews in molecular, cellular and developmental biology. 1998. Cole S P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of cancer therapy: getting personal. American journal of human genetics. 1998. Krynetski E Y, et al. PubMed

LinkOuts

Clinical Trials

These are trials that mention antineoplastic agents and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.